上海医药(601607.SH)：拟挂牌转让所持有的中美施贵宝30%股权

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) plans to optimize its investment structure and maximize asset value by publicly transferring its 30% stake in Celgene Corporation through a property trading agency [1] Group 1 - The transfer will be conducted via public listing, with a minimum listing price set at RMB 1,023.192 million [1] - The transfer process will require completion of relevant state-owned asset evaluation and management procedures [1] - The final transfer price will be determined based on the results of the public listing transaction [1]